0001683168-26-001737
SEC filingXenetic Biosciences, Inc. reported a net loss of $2.7 million for fiscal year 2025, an improvement from a $4.0 million loss in 2024. Total revenue was $3.0 million, derived entirely from royalty revenue, representing a 19% year-over-year increase. The company's operating loss narrowed to $2.8 million from $4.2 million, driven by reduced general and administrative expenses. Research and development expenses remained elevated at $3.1 million, reflecting continued investment in the DNase technology platform. The company ended the year with $7.9 million in cash, bolstered by a $4.0 million public offering in October 2025, providing liquidity to advance its immuno-oncology programs. The strategic review process initiated to maximize shareholder value remains ongoing.
Xenetic Biosciences reported a net loss of $2.7 million for the fiscal year ended December 31, 2025, a significant improvement from the $4.0 million loss in the prior year. This reduction in loss was primarily driven by a 19% increase in royalty revenue to $3.0 million and a 19.6% decrease in general and administrative expenses to $2.7 million. The company's loss from operations narrowed to $2.8 million from $4.2 million in 2024. Research and development expenses decreased slightly to $3.1 million from $3.3 million, though this included a $0.7 million impairment charge in 2024 related to legacy technology. The company's cash position improved to $7.9 million at year-end, supported by net proceeds of $4.0 million from an October 2025 public offering.
Revenue for FY2025 consisted entirely of royalty revenue of $3.0 million, representing a $0.5 million increase from the $2.5 million reported in FY2024. This royalty revenue is generated from a sublicense agreement with Takeda Pharmaceutical Co. Ltd. related to the company's PolyXen technology for blood coagulation disorders. The company noted that royalty payments are based on single-digit royalties on net sales of certain covered products. No other revenue streams were reported, and the company continues to focus its internal development efforts on advancing its DNase technology platform for oncology applications.
The company's operating margin improved as operating losses decreased by 32.6% year-over-year. This improvement was driven by both revenue growth and cost containment efforts. General and administrative expenses decreased by $0.7 million primarily due to reduced severance costs compared to the prior year when the company incurred expenses related to separation agreements with former executives. Research and development expenses, while slightly lower, remained substantial at $3.1 million as the company continues to invest in preclinical development of its DNase technology through collaborations with academic institutions and contract research organizations.
Net cash used in operating activities was $2.3 million for FY2025, an improvement from $2.8 million in the prior year. The company's cash position increased to $7.9 million at December 31, 2025, from $6.2 million at the end of 2024, primarily due to $4.0 million in net proceeds from an October 2025 public offering. Total assets were $8.4 million, with current assets of $8.0 million. Total liabilities were minimal at $1.0 million, consisting primarily of accounts payable and accrued expenses. Stockholders' equity improved to $7.4 million from $6.0 million, though the accumulated deficit increased to $199.9 million.
The company is conducting a strategic review process to maximize shareholder value, considering alternatives including the sale of the company or its assets, or a business combination. Management remains committed to advancing the DNase technology as an adjunctive therapy for pancreatic cancer and other solid tumors. The company anticipates requiring additional capital to complete clinical trials and obtain regulatory approvals for its drug candidates. Key risk factors include the uncertainty of the strategic review outcome, dependence on the success of DNase technology, need for substantial additional funding, and competitive pressures in the biotechnology industry.